Clear market notes built around the JSE, the rand, and what matters locally.

2026-07-18 13:30 • The Motley Fool Positive Axe Cap view: Selective

Wall Street analysts are bullish on Viking Therapeutics (VKTX), with a consensus price target of $91 representing a potential 150% return. The optimism centers on VK2735, a dual-formulation weight-loss drug showing promising phase 2 efficacy data. However, key phase 3 results won't arrive until late 2027-2028, and some phase 2 oral trial tolerability concerns exist. Cautious investors may want to wait for upcoming maintenance trial results before investing.

Axe note: Wall Street loves Viking Therapeutics’ weight-loss drug, but long trial timelines and side effect worries suggest caution.

2026-07-18 13:20 • The Motley Fool Positive Axe Cap view: Selective

SK Hynix, now trading on U.S. exchanges via ADR, is compared to Micron as a memory chip investment. SK Hynix leads the HBM market with 56% share and has a strategic partnership with Nvidia, while Micron has a longer track record but entered HBM later. Both companies are benefiting from strong AI infrastructure demand, though the volatile memory chip market poses risks. The article recommends SK Hynix for new investments despite Micron's lower valuation.

Axe note: SK Hynix’s HBM edge and Nvidia tie give it a local angle that tips the scales despite Micron’s value appeal.

2026-07-18 13:15 • The Motley Fool Negative Axe Cap view: Bearish

Pfizer's attractive 7% dividend yield masks significant risks as the company faces a patent cliff with major drugs losing protection in 2027-2028. With a dividend payout ratio over 130% and limited new drug candidates in the pipeline, investors are concerned about the sustainability of the dividend. However, the company has cash reserves and debt options to maintain payments, and management has prioritized dividend preservation.

Axe note: Pfizer’s generous dividend yield hides serious sustainability concerns amid patent expiries and a thin drug pipeline.